The DDR-immune fitness score: a biomarker for guiding parp and immunotherapy synergy in extensive-stage small cell lung cancer

The DDR-IF score unifies measures of genomic instability and immune contexture to identify a therapeutically vulnerable subset of ES-SCLC patients most likely to benefit from PARP-ICB synergy. It represents a promising, though exploratory, framework for personalizing immunotherapy in ES-SCLC, whose clinical utility requires confirmation in prospective multicenter trials.